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Short-chain fatty acids (SCFAs), produced from fermentation of dietary fibre by the gut micro-
biota, have been suggested to modulate energy metabolism. Previous work using rodent
models has demonstrated that oral supplementation of the SCFA propionate raises resting
energy expenditure (REE) by promoting lipid oxidation. The objective of the present study was
to investigate the effects of oral sodium propionate on REE and substrate metabolism in
humans. Eighteen healthy volunteers (9 women and 9 men; age 25  1 years; body mass index
24.1  1.2 kg/m2) completed 2 study visits following an overnight fast. Tablets containing a
total of 6845 mg sodium propionate or 4164 mg sodium chloride were provided over the 180-
minute study period in random order. REE and substrate oxidation were assessed by indirect
calorimetry. Oral sodium propionate administration increased REE (0.045  0.020 kcal/min;
P = .036); this was accompanied by elevated rates of whole-body lipid oxidation
(0.012  0.006 g/min; P = .048) and was independent of changes in glucose and insulin con-
centrations. Future studies are warranted to determine whether the acute effects of oral
sodium propionate on REE translate into positive improvements in long-term energy balance in
humans.
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1 | INTRODUCTION
A number of studies have shown that increased intake of dietary fibre
prevents weight gain and its related metabolic comorbidities.1 This
association may be attributable to the influence of dietary fibre on the
composition and activities of the gut microbiome.2 The major end-
products of dietary fibre fermentation by the gut microbiota are the
short-chain fatty acids (SCFAs) acetate, propionate and butyrate,2
which have been shown to modulate host metabolism via effects on
metabolic pathways and receptor-mediated mechanisms at different
tissue and organ sites.3 Specifically, SCFAs act as ligands for G-pro-
tein-coupled receptors free fatty acid receptor (FFAR)2 and FFAR3,
which are expressed throughout the body and modulate energy
homeostasis.4 The stimulation of FFAR2 on intestinal enteroendocrine
L-cells by SCFAs has been shown to enhance the release and circulat-
ing levels of the anorectic hormones peptide YY (PYY) and glucagon-
like peptide-1 (GLP-1).5 Enhanced colonic SCFA production has there-
fore been suggested to improve long-term energy balance by reducing
appetite and energy intake.4 Our previous work observed that acute
oral supplementation with an inulin-propionate ester, designed to spe-
cifically increase delivery of propionate to the human colon, reduced
energy intake, which was associated with enhanced PYY and GLP-1
release.6 In a follow-up investigation, daily oral supplementation with
inulin-propionate ester for 24 weeks prevented body weight gain and
visceral adipose tissue accumulation in overweight adults6; however,
there was no detectable change in anorectic gut hormone release or
energy intake after long-term colonic propionate delivery, suggesting
that gut-derived propionate has positive effects on energy balance and
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body weight, independently of alterations in energy intake. Indeed, a
number of studies have shown that mice receiving a gut microbial
transplant that promotes caecal propionate production display no
changes in energy intake, yet body composition and glycaemic control
are improved.7 Furthermore, oral administration of sodium propionate
in mice has also been shown to prevent gains in body weight without
reducing energy intake.8,9 Orally supplemented SCFAs would be rap-
idly absorbed from the upper gastrointestinal tract, suggesting that
propionate could affect energy metabolism by entering the portal and
systemic circulation. An intraperitoneal injection of propionate in mice
was found to promote sympathetic nervous system activity, via stimu-
lation of FFAR3 expressed at the level of the sympathetic ganglion,
elevating heart rate and energy expenditure.10 The addition of sodium
propionate to the feed of mice has also been reported to protect
against diet-induced obesity by enhancing energy expenditure via a
promotion of lipid oxidation in hepatic and adipose tissue.8
There is currently limited in vivo evidence to support an effect of
gut-derived propionate on energy expenditure and substrate oxida-
tion in humans. Nevertheless, a recent report in overweight and
obese men showed that a rectal infusion of a SCFA mixture high in
propionate increased fasting resting energy expenditure (REE) by
stimulating lipid oxidation.11 In the present study we tested the
hypothesis that acute oral intake of sodium propionate would
increase REE and rates of lipid oxidation.
2 | METHODS
All subjects provided informed, written consent to participate in the
study, which was approved by the Wales Research Ethics Committee
6 (15/WA/0415) and carried out in accordance with the Declaration
of Helsinki. Men and women aged 18 to 65 years, with a body mass
index of 18 to 35 kg/m2 were recruited. A detailed methodology and
protocol schematic is presented in the File S1 and Figure S1 in File S1.
Volunteers completed 2 study visits separated by >2 days. The
mean  SD (range) period between study visits was 5  2 (2-10)
days. Volunteers were requested to refrain from strenuous exercise
and alcohol consumption and to consume a standard evening meal
prior to fasting overnight for >10 hours before the study visits.
Volunteers arrived at the National Institute of Health Research
(NIHR) Imperial Clinical Research Facility between 8:00 and 9:00 AM
and were asked to void their bladder, and body weight was then
recorded to the nearest 0.1 kg. Urine was collected for the remainder
of the study visit to provide an estimate of urinary nitrogen excretion
from urea concentration.12 A cannula was inserted into an antecubital
vein and 2 fasting blood samples were collected >5 minutes apart.
Further blood samples were taken at 60, 120 and 180 minutes.
In a randomized, double-blind, crossover design, volunteers were
provided with tablets containing 1369 mg sodium propionate (propio-
nate trial) or 833 mg sodium chloride (sodium-matched control trial)
at 0, 30, 60, 90 and 120 minutes. The total amount of sodium propio-
nate ingested over the study visit was 6845 mg (71 mmol). The pro-
pionate and control tablets (Table S1 in File S1) had an enteric
coating (Acryl-EZE; Colorcon, Dartford, UK), resistant to the pH of
gastric fluid, that readily dissolves at a pH >5.5.13
Volunteers lay semi-recumbent under an indirect calorimeter
canopy (GEM Nutrition, Daresbury, UK) between −20 and 0 minutes,
40 and 60 minutes, 100 and 120 minutes and 160 and 180 minutes.
The calorimeter was calibrated with “zero” (0.00% O2 and 0.00%
CO2) and “span” (20.00% O2, 1.00% CO2) gases (BOC Gases, Guild-
ford, UK) and REE, respiratory exchange ratio (RER) and carbohydrate
and lipid oxidation rates were calculated at each time point from
mean values of VO2 and VCO2, with adjustment for urinary nitrogen
excretion.12,14 Heart rate and blood pressure were measured at 0, 60,
120 and 180 minutes (SureSigns VM4, Phillips, Cambridge, Massa-
chusetts). Volunteers were asked to complete 100-mm visual ana-
logue scales to assess subjective hunger and nausea at 0, 30, 60, 90,
120, 150 and 180 minutes.
3 | RESULTS
Data were analysed from 18 volunteers who completed the 2 study
visits (9 women and 9 men; age 25  1 years; body mass index
24.1  1.2 kg/m2) and no significant differences were found
between trials in baseline values for all measurements (Table S2 in
File S1). Levels of propionate in peripheral blood were higher in the
propionate trial (Figure 1A,B; mean difference 1.19  0.34 μmol/L;
effect of trial P = .003), with values significantly raised at
180 minutes compared with control (3.04  0.26 μmol/L vs
5.25  0.65 μmol/L; P = .005). There were no differences in circulat-
ing levels of acetate (Figure 1C,D; mean difference 2.64  3.99
μmol/L; effect of trial P = .518) or butyrate (Figure 1E,F; mean differ-
ence −0.09  0.21 μmol/L; effect of trial P = .657) between trials.
The REE was significantly higher after propionate compared with
control (Figure 2A,B), with a mean difference of 0.045  0.020 kcal/
min (effect of trial P = .036). The increase in REE was accompanied
by a significantly lower RER in the propionate trial (Figure 2C,D;
0.88  0.02 vs 0.85  0.02; effect of trial P = .040), with higher lipid
oxidation rates compared with control supplementation (Figure 2E,F),
with a mean difference of 0.012  0.006 g/min (effect of trial
P = .048). There were no differences in rates of carbohydrate oxida-
tion (Figure 2G,H; mean difference −0.014  0.13 g/min; effect of
trial P = .283) or protein oxidation (control 0.062  0.006 g/min vs
propionate 0.059  0.005 g/min; P = .535) between trials.
The effects of propionate on energy homeostasis were not
related to differences in circulating levels of glucose (Figure S2A,B in
File S1; mean difference 0.4  0.9 mmol/L; effect of trial P = .666)
or insulin (Figure S2C,D in File S1; mean difference −0.1  0.9 μU/
mL; effect of trial P = .742). There was no mean difference between
trials in levels of non-esterified fatty acids (NEFA; Figure 2E,F; mean
difference −0.02  0.05 mmol/L; effect of trial P = .767), but there
was a significant time × trial interaction (P = .017). Post hoc tests
revealed no differences at any time point, with a trend for NEFA
levels to be lower in the propionate trial at 180 minutes
(0.686  0.057 mmol/L vs 0.595  0.049 mmol/L; P = .082). There
were no significant differences in glycerol concentration (Figure S4A
in File S1; mean difference − 0.5  3.0 μmol/L; effect of trial
P = .865) between study visits. PYY levels were measured at baseline
and 180 minutes, and a significant time × trial interaction (P = .039)
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revealed raised concentration after propionate at 180 minutes com-
pared with control (33.6  7.7 pmol/L vs 56.9  8.6 pmol/
L; P = .012).
There were no significant differences in heart rate (Figure S5A in
File S1; mean difference 1.0  0.8 bpm; effect of trial P = .197) or
mean arterial blood pressure (Figure S5B in File S1; mean difference
1.0  0.9 mm Hg; effect of trial P = .267) between study visits. Vol-
unteers reported no differences in subjective hunger between trials
(Figure S6A in File S1; mean difference −2.2  2.4 mm; effect of trial
P = .370), yet subjective nausea was significantly raised in the propio-
nate trial (Figure S6B in File S1; mean difference 3.2  1.2 mm;
effect of trial P = .013).
4 | DISCUSSION
Previous work conducted in mice has reported increased energy
expenditure with the addition of sodium propionate to the diet.8 A
FIGURE 1 The effect of oral sodium propionate supplementation on short chain fatty acid levels in peripheral blood. A, Propionate (time × trial
P = .043) and B, Propionate incremental area under the curve (iAUC; P = .021). C, Acetate (time × trial P = .209) and D, Acetate iAUC (P = .761).
E, Butyrate (time × trial P = .272) and F, Butyrate iAUC (P = .587). All data expressed as mean  SEM (n = 18)
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direct translation of these findings from murine models to humans
should not be assumed, primarily because of substantial species dif-
ferences in whole-body REE (expressed per unit mass) and the rela-
tive size and contribution of different tissue and organ sites to REE;15
however, in the present study we did observe that acute oral
administration of 6845 mg sodium propionate increased REE in over-
night fasted humans independently of changes in glucose or insulin
levels. The present study also corroborates a recent report in over-
weight humans that rectal infusion of an SCFA mixture high in levels
of propionate enhances REE in the fasted state.11 A common finding
FIGURE 2 Effect of oral sodium propionate supplementation on resting energy expenditure and substrate oxidation. A, Resting energy expendi-
ture (REE; time × trial P = .388) and B, REE incremental area under the curve (iAUC; P = .036). C, Respiratory exchange ratio (RER; time × trial
P = .158) and D, Mean RER (P = .040). E, Lipid oxidation (time × trial P = .075) and F, Lipid oxidation iAUC (P = .019). G, Carbohydrate
oxidation (time × trial P = .199) and H, Carbohydrate oxidation iAUC (P = .338). All data expressed as mean  SEM (n = 18)
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in these murine and human investigations is that propionate
increased REE by promoting the rates of whole-body lipid oxidation.
In the present study, we observed an increase in the peripheral con-
centrations of propionate in peripheral blood after oral sodium propi-
onate supplementation. Previous investigations in humans would
indicate that the majority (>90%) of propionate absorbed from the
gastrointestinal tract is extracted and metabolized by the liver before
entering the systemic circulation.16 This suggests that the changes in
REE and substrate handling recorded in the present investigation
could be primarily at the hepatic level. Indeed, work using hepatic tis-
sue from SCFA-fed mice has demonstrated that propionate increases
the expression of mitochondrial uncoupling protein 2 (UCP2) and the
ratio of AMP:ATP, thus inhibiting lipogenesis and stimulating rates of
β-oxidation.8 This may provide a metabolic explanation for our previ-
ous observation that long-term colonic propionate delivery reduced
intrahepatocellular lipid content in adults with non-alcoholic fatty
liver disease.6 Nevertheless, the increased levels of propionate in
peripheral blood could also modulate metabolic processes to promote
lipid oxidation at other organ sites, including adipose tissue and skele-
tal muscle.3 Further work is required to fully elucidate the contribu-
tion of different organ sites to the observed effects of oral sodium
propionate on whole-body REE and lipid oxidation.
Unlike a previous investigation performed in mice,10 we did not
record an effect of propionate on sympathetic nervous system activ-
ity, as measured by changes in heart rate and blood pressure. This
may be explained by the much larger dose and route of administra-
tion of propionate (1 g/kg body weight by intraperitoneal injection) in
the rodent study. In humans, daily propionate production is estimated
at 29.5 mg/kg body weight,4 thus the acute dose of sodium propio-
nate provided in the present study represents a substantial increase
in habitual propionate absorption from the gut (2089  106 mg/d
calculated from volunteer body weights). The present methodology is
unable to differentiate the contribution of exogenous and endoge-
nous sources to the recorded increase in whole-body lipid oxidation,
however, indirect evidence would indicate this is unlikely to be
explained solely by oxidation of the ingested propionate. Propionate
oxidation produces an RER of 0.86, which is higher than that
recorded throughout the propionate trial, suggesting an enhanced
oxidation of endogenous lipids that yield a lower RER. We also
observed that the intervention affected endogenous lipid metabolism,
as shown by the significant effect on NEFA levels, with post hoc tests
demonstrating a trend for a reduction in circulating NEFA at
180 minutes when systemic propionate levels were raised. The stim-
ulation of FFAR2 expressed on adipose tissue has previously been
shown to inhibit lipolysis and the levels of circulating NEFA17 and to
stimulate lipid expenditure in other tissues, including muscle and
liver.18 A recent stable isotope study in humans has also shown that
a portion of gut-derived propionate is utilised in hepatic gluconeo-
genesis rather than being directly oxidized.19 The fraction of propio-
nate incorporated into glucose was reported to be relatively small
(6%), but the postprandial study conditions employed may underesti-
mate the amounts of propionate used for gluconeogenesis in the
overnight fasted conditions of the present study. Rates of gluconeo-
genesis increase throughout the post-absorptive state20 and it is fea-
sible that, after >12 hours of fasting, greater amounts of propionate
would be used to sustain the higher rates of endogenous glucose
production.
Propionate levels became significantly increased in peripheral
blood at 180 minutes; thus, it is unlikely that the complete absorption
and bioavailability of the ingested sodium propionate was measured
in the present study protocol. It would be of interest to determine
how long the metabolic effects of the oral sodium propionate dose
persist in the fasted state and the impact on energy metabolism in
other physiological states, including postprandially and during physi-
cal activity. The maximum ATP yield from propionate oxidation is
18 ATP/mol, equivalent to 131.4 kcal/mol.21 Assuming all propionate
was oxidized, the ingested sodium propionate had a maximum energy
recovery of 9.3 kcal, and thus the observed 0.045 kcal/min increase
in REE would need to be maintained for >3.5 hours to achieve a neg-
ative energy balance. The intervention may also have influenced
energy balance by reducing energy intake, as we have previously
observed that acutely increasing colonic propionate levels reduces ad
libitum food intake.6 Indeed, we observed an increase in the anorectic
gut hormone PYY at the end of the study period that may have modi-
fied energy intake had it been quantified. Consequently both energy
expenditure and intake would need to be measured to determine the
extent to which oral sodium propionate administration acutely modu-
lates energy balance. This would provide evidence of the utility of
sodium propionate as an intervention to improve chronic energy bal-
ance and body weight management in humans.
In summary, the present study provides the first direct evidence
that acute oral administration of sodium propionate stimulates REE
and whole-body lipid oxidation in humans, thus corroborating the
outcome of investigations conducted in mice.8 Murine models show
that chronic sodium propionate ingestion promotes benefits to body
weight and glucose homeostasis8,9 and long-term studies are needed
to demonstrate the same efficacy in humans.
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